Justin Smith
Stock Analyst at Bernstein
(4.16)
# 1,583
Out of 4,707 analysts
179
Total ratings
60.5%
Success rate
9.8%
Average return
Main Sectors:
Stocks Rated by Justin Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: MRK Merck KGaA | Maintained: Hold | €112.00 → €151.00 | €134.60 | +12.18% | 2 | Aug 7, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | kr 175.00 → kr 200.00 | kr 292.00 | -31.51% | 3 | Aug 5, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €107.00 → €106.21 | €74.70 | +42.18% | 4 | Aug 4, 2026 | |
| LON: GSK GSK plc | Maintained: Buy | 2,825p → 3,010p | 1,797p | +67.55% | 25 | Aug 3, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 18,900p → 20,200p | 11,876p | +70.09% | 34 | Jul 29, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €877.00 → €986.00 | €869.20 | +13.44% | 13 | Jul 28, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | CHF 395.00 → CHF 434.50 | CHF 350.50 | +23.97% | 26 | Jul 27, 2026 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | n/a | $556.00 | - | 9 | Jul 24, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 125.00 → CHF 133.00 | CHF 111.80 | +18.96% | 2 | Jul 22, 2026 | |
| NVS Novartis AG | Initiated Coverage: Hold | n/a | $137.70 | - | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | kr 1,015 → kr 1,400 | kr 2,170 | -35.48% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $33.53 | n/a | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $27.79 | n/a | 8 | Aug 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €10.50 → €2.90 | €0.82 | n/a | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €22.00 → €21.50 | €10.00 | n/a | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $85 → $51 | $64.69 | n/a | 10 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $104 | $148.46 | n/a | 4 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €45.80 → €71.00 | €38.79 | n/a | 7 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €69.00 → €70.00 | €44.69 | n/a | 6 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $54.07 | n/a | 2 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $172 → $140 | $248.78 | n/a | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $48.54 | n/a | 1 | Sep 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.99 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $22.45 | n/a | 1 | Feb 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $78 | $1,123.91 | n/a | 1 | Apr 7, 2016 |
Merck KGaA
Aug 7, 2026
Maintained: Hold
Price Target: €112.00 → €151.00
Current: €134.60
Upside: +12.18%
Novo Nordisk A/S
Aug 5, 2026
Maintained: Sell
Price Target: kr 175.00 → kr 200.00
Current: kr 292.00
Upside: -31.51%
Sanofi
Aug 4, 2026
Maintained: Buy
Price Target: €107.00 → €106.21
Current: €74.70
Upside: +42.18%
GSK plc
Aug 3, 2026
Maintained: Buy
Price Target: 2,825p → 3,010p
Current: 1,797p
Upside: +67.55%
AstraZeneca PLC
Jul 29, 2026
Maintained: Buy
Price Target: 18,900p → 20,200p
Current: 11,876p
Upside: +70.09%
argenx SE
Jul 28, 2026
Maintained: Buy
Price Target: €877.00 → €986.00
Current: €869.20
Upside: +13.44%
Roche Holding AG
Jul 27, 2026
Maintained: Buy
Price Target: CHF 395.00 → CHF 434.50
Current: CHF 350.50
Upside: +23.97%
Lonza Group AG
Jul 24, 2026
Maintained: Buy
Price Target: n/a
Current: $556.00
Upside: -
Novartis AG
Jul 22, 2026
Rated: Hold
Price Target: CHF 125.00 → CHF 133.00
Current: CHF 111.80
Upside: +18.96%
Novartis AG
Mar 19, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $137.70
Upside: -
Feb 23, 2026
Maintained: Sell
Price Target: kr 1,015 → kr 1,400
Current: kr 2,170
Upside: -35.48%
Sep 8, 2025
Reiterated: Sell
Price Target: n/a
Current: $33.53
Upside: n/a
Aug 17, 2025
Maintained: Hold
Price Target: n/a
Current: $27.79
Upside: n/a
Mar 31, 2025
Downgraded: Hold
Price Target: €10.50 → €2.90
Current: €0.82
Upside: n/a
Dec 10, 2024
Maintained: Buy
Price Target: €22.00 → €21.50
Current: €10.00
Upside: n/a
Mar 11, 2024
Downgraded: Hold
Price Target: $85 → $51
Current: $64.69
Upside: n/a
Mar 11, 2024
Downgraded: Sell
Price Target: $104
Current: $148.46
Upside: n/a
Nov 17, 2023
Upgraded: Buy
Price Target: €45.80 → €71.00
Current: €38.79
Upside: n/a
Nov 17, 2023
Maintained: Buy
Price Target: €69.00 → €70.00
Current: €44.69
Upside: n/a
Feb 27, 2023
Upgraded: Buy
Price Target: n/a
Current: $54.07
Upside: n/a
Nov 8, 2022
Downgraded: Hold
Price Target: $172 → $140
Current: $248.78
Upside: n/a
Sep 3, 2019
Upgraded: Buy
Price Target: n/a
Current: $48.54
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: n/a
Current: $12.99
Upside: n/a
Feb 24, 2017
Downgraded: Hold
Price Target: n/a
Current: $22.45
Upside: n/a
Apr 7, 2016
Initiated Coverage: Hold
Price Target: $78
Current: $1,123.91
Upside: n/a